Consumer medicine information

APO-Cephalexin Capsules

Cefalexin

BRAND INFORMATION

Brand name

APO-Cephalexin Capsules

Active ingredient

Cefalexin

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using APO-Cephalexin Capsules.

SUMMARY CMI

APO-Cephalexin

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using APO-Cephalexin?

APO-Cephalexin contains the active ingredient cefalexin monohydrate. APO-Cephalexin is used to treat infections in different parts of the body caused by bacteria.

For more information, see Section 1. Why am I using APO-Cephalexin? in the full CMI.

2. What should I know before I use APO-Cephalexin?

Do not use if you have ever had an allergic reaction to APO-Cephalexin or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use APO-Cephalexin? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with APO-Cephalexin and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use APO-Cephalexin?

  • Continue taking APO-Cephalexin for as long as your doctor tells you
  • It is important to complete the full course prescribed by your doctor, even if you begin to feel better after a few days. If you do not, the bacteria causing your infection may not clear completely or your symptoms may return.

More instructions can be found in Section 4. How do I use APO-Cephalexin? in the full CMI.

5. What should I know while using APO-Cephalexin?

Things you should do
  • Tell your doctor, dentist or pharmacist you visit that you are using APO-Cephalexin.
  • Tell your doctor immediately if you become pregnant or start breastfeeding.
  • If you are going to have surgery, tell your surgeon or anesthetist.
  • If you are diabetic, check with your doctor or pharmacist before using urine sugar tests.
Things you should not do
  • Do not stop using this medicine because you are feeling better, unless advised by a doctor.
  • Do not give your medicine to anyone else, even if they have the same condition or symptoms as you.
  • Do not take a double dose to make up the dose that you missed
Driving or using machines
  • Be careful as this medicine may cause dizziness or tiredness
  • Children may also be affected so they should be watched carefully if riding bikes or climbing
Drinking alcohol
  • There are no known interactions
Looking after your medicine
  • Store below 25°C protected from light and moisture
  • Keep your medicine in its original packaging until it is time to take it

For more information, see Section 5. What should I know while using APO-Cephalexin? in the full CMI.

6. Are there any side effects?

Common side effects may include dizziness, tiredness, weakness or headache, mild diarrhoea or stomach upsets/pain, oral or vaginal thrush, itching in the genital or anal areas. Serious side effects include fever, itching or any type of skin rash, blistering or peeling, aching or swollen muscles or joints, severe vomiting, diarrhoea and/or stomach pain, skin or eyes yellowing, pale stools, dark urine, bleeding or bruising more easily than normal, feeling agitated, confused or seeing or hearing things, symptoms of an allergic reaction (eg. shortness of breath, difficulty breathing, swelling of face, lips, tongue, throat)

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

APO-Cephalexin

Active ingredient: cefalexin monohydrate


Consumer Medicine Information (CMI)

This leaflet provides important information about using APO-Cephalexin. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using APO-Cephalexin.

Where to find information in this leaflet:

1. Why am I using APO-Cephalexin?
2. What should I know before I use APO-Cephalexin?
3. What if I am taking other medicines?
4. How do I use APO-Cephalexin?
5. What should I know while using APO-Cephalexin?
6. Are there any side effects?
7. Product details

1. Why am I using APO-Cephalexin?

APO-Cephalexin contains the active ingredient cefalexin monohydrate. APO-Cephalexin belongs to a group of antibiotics called cephalosporins that are closely related to penicillins. It works by killing the bacteria causing your infection or by stopping its growth.

APO-Cephalexin is used to infections in different parts of the body caused by bacteria such as:

  • respiratory tract (chest, lungs, tonsils or throat)
  • sinuses
  • ears (middle ear infection)
  • skin
  • genitourinary tract (kidney, bladder or prostate).

Cefalexin will not work against infections caused by viruses such as colds or the flu.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed cefalexin for another reason.

This medicine is available only with a doctor's prescription.

There is no evidence that this medicine is addictive.

2. What should I know before I use APO-Cephalexin?

Warnings

Do not use APO-Cephalexin if:

  • you are allergic to cefalexin (or other cephalosporins), or any of the ingredients listed at the end of this leaflet.
  • Always check the ingredients to make sure you can use this medicine.
  • if it is after the expiry date printed on the pack
  • if the packaging is torn or shows sign of tampering

Do not take this medicine if you have had a serious allergic reaction to penicillins. Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin

Check with your doctor if you:

  • have any other medical conditions
  • take any medicines for any other condition
  • have allergies to cephalosporins, penicillins or other antibiotics
  • have allergies to any other medicines, foods, preservatives or dyes
  • have or have had an intolerance or allergic reason to lactose
  • have or have had kidney or liver disease
  • have or have had severe bowel conditions / disease

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

If you have not told your doctor about any of the above, tell them before you start taking this medicine.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with APO-Cephalexin and affect how it works:

  • Probenecid (used to treat gout or prolong the action of certain antibiotics)
  • Metformin (used to treat diabetes)

These medicines may be affected by cefalexin or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect APO-Cephalexin.

4. How do I use APO-Cephalexin?

How much to take / use

Your doctor or pharmacist will tell you how many capsules you will need to take. This depends on your infection, your condition and whether or not you are taking any other medicines.

  • Adults: The usual adult dose is one 250mg capsule taken every six hours. Your doctor may recommend a different dose depending on your condition.
  • Children: Your child's doctor will tell you how much cefalexin your child should take. This will depend on your child's age, weight and the type of infection.

Continue taking APO-Cephalexin for as long as your doctor tells you. It is important to complete the full course prescribed by your doctor, even if you begin to feel better after a few days. If you do not, the bacteria causing your infection may not clear completely or your symptoms may return.

When to take / use APO-Cephalexin

  • It does not matter if you take APO-Cephalexin with or without food

How to take APO-Cephalexin

  • Swallow the capsules with a glass of water

If you forget to use APO-Cephalexin

APO-Cephalexin should be used regularly at the same time each day. If you miss your dose at the usual time and it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take it as soon as you remember, and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for the dose you missed.

If you are not sure what to do, ask your doctor or pharmacist. Ask your pharmacist for some hints if you have trouble remembering to take your medicine.

If you use too much APO-Cephalexin

If you think that you have used too much APO-Cephalexin, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using APO-Cephalexin?

Things you should do

Tell any other doctors, dentists, and pharmacists who are treating you that you are taking this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine. It may affect other medicines used during surgery.

If you become pregnant or start to breastfeed while taking this medicine, tell your doctor immediately.

If you are about to have any blood tests, tell your doctor that you are taking this medicine. It may interfere with the results of some tests.

If you are diabetic, check with your doctor or pharmacist before using urine sugar tests. Cefalexin may affect the results of some of these tests.

Keep all your doctor's appointments so that your progress can be checked.

If the symptoms of your infection do not improve within a few days, or if they become worse, tell your doctor.

If you get severe diarrhoea tell your doctor, pharmacist or nurse immediately. Do this even if it occurs several weeks after cefalexin has been stopped. Diarrhoea may mean that you have a serious condition affecting your bowel. You may need urgent medical care. Do not take any medicine for diarrhoea without first checking with your doctor or pharmacist.

If you get a sore white mouth or tongue while taking or soon after stopping cephalexin, tell your doctor. Also tell your doctor if you get vaginal itching or discharge. This may mean you have fungal infection called thrush.

Things you should not do

  • unless advised by your doctor, o not stop using this medicine because you are feeling better. If you do not complete the full course prescribed by your doctor, all the bacteria causing your infection may not be killed. These bacteria may continue to grow and multiply so that your infection may not clear completely, or it may return.
  • do not give your medicine to anyone else, even if they have the same condition as you
  • do not take your medicine to treat any other complaints unless your doctor or pharmacist tells you to

Driving or using machines

Be careful before you drive or use any machines or tools until you know how APO-Cephalexin affects you.

APO-Cephalexin may cause dizziness or tiredness in some people.

Children may also be affected so they should be carefully watched if riding bikes or climbing.

Drinking alcohol

Tell your doctor if you drink alcohol.

Looking after your medicine

  • Store below 25°C

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

When to discard your medicine (as relevant)

If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, ask your pharmacist what to do with any medicine that is left over.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
  • oral thrush (white, furry, sore tongue and mouth)
  • vaginal thrush (sore and itchy vagina and/or discharge)
  • itching in the genital / anal areas
  • mild diarrhoea
  • mild stomach upsets, such as indigestion, feeling sick and/or being sick (nausea or vomiting)
  • abdominal pain
  • dizziness, tiredness, weakness or headache
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
  • fever
  • itching or any type of skin rash or blistering, peeling or flaking skin
  • aching or swollen muscles, joints or joint pain.
  • severe vomiting and/or stomach pain
  • yellowing of the skin or eyes, and/or pale stools, dark urine (jaundice)
  • watery and severe diarrhoea, which may also be bloody
  • bleeding or bruising more easily than normal, frequent infections such as fever, severe chills, sore throat or mouth ulcers
  • feeling agitated, confused or seeing or hearing things that are not there.
  • severe abdominal cramps or stomach cramps
  • seizure potential
  • severe blisters and bleeding in mucosal sites (such as lips, eyes, mouth, nose, genitals) that may cause the skin to peel, sometimes occurring with fever and flu-like symptoms
  • symptoms of an allergic reaction including cough, shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What APO-Cephalexin contains

Active ingredient
(main ingredient)
cefalexin monohydrate
Other ingredients
(inactive ingredients)
  • lactose monohydrate
  • gelatin
  • iron oxide yellow
  • brilliant blue FCF
  • sunset yellow FCF
  • titanium dioxide
  • magnesium stearate
  • TekPrint SW-9008 black ink
  • purified water
Potential allergenslactose; may contain trace amounts of sulfites

Do not take this medicine if you are allergic to any of these ingredients.

What APO-Cephalexin looks like

250 mg capsules (AUST R 73870):
Dark green and white, self-locked hard gelatin capsules of size 2, imprinted with RX656 in black ink, containing white to off-white granular powder/pellets.

500 mg capsules (AUST R 133852)
Dark green and light green, self-locked hard gelatin capsules of size 0, imprinted with RX657 in black ink, containing white to off-white granular powder/pellets.

Blister packs of 20 capsules.

Who distributes APO-Cephalexin

Arrotex Pharmaceuticals Pty Ltd
15 – 17 Chapel Street
Cremorne VIC 3121
www.arrotex.com.au

This leaflet was prepared in December 2023.

Published by MIMS March 2024

BRAND INFORMATION

Brand name

APO-Cephalexin Capsules

Active ingredient

Cefalexin

Schedule

S4

 

1 Name of Medicine

Cefalexin monohydrate.

2 Qualitative and Quantitative Composition

Each capsule contains cefalexin monohydrate equivalent to 250 mg or 500 mg cefalexin anhydrous as the active ingredient.

Excipients with known effect.

Contains sugars as lactose.
For the full list of excipients see Section 6.1 List of Excipients.

3 Pharmaceutical Form

250 mg capsules.

Dark green and white, self-locked hard gelatin capsules of size 2, imprinted with RX656 in black ink, containing white to off-white granular powder/pellets.

500 mg capsules.

Dark green and light green, self-locked hard gelatin capsules of size 0, imprinted with RX657 in black ink, containing white to off-white granular powder/pellets.

4 Clinical Particulars

4.1 Therapeutic Indications

Cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms.

Respiratory tract infections.

Caused by S. pneumoniae and group A β-haemolytic Streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefalexin is generally effective in the eradication of Streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of rheumatic fever are not available at present).

Bacterial sinusitis.

Caused by Streptococci, S. pneumoniae and S. aureus (methicillin sensitive only).

Otitis media.

Due to S. pneumoniae, Staphylococci.

Skin and skin structure infections.

Caused by Staphylococci and/or Streptococci.

Genitourinary tract infections, including acute prostatitis.

Caused by E. coli, P. mirabilis and Klebsiella sp.
The effectiveness of cefalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cefalexin is not indicated in these conditions.

Note.

Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cefalexin. Renal function studies should be performed when indicated.

4.2 Dose and Method of Administration

APO-Cephalexin Capsules are intended for oral administration.

Adults.

The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 250 mg every six hours.
For streptococcal pharyngitis or tonsillitis, mild, uncomplicated urinary tract infections, and skin and skin structure infections, a dosage of 500 mg may be administered every twelve hours.
For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of cefalexin greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.
Twice daily dosing is not recommended when doses larger than 1 g daily are administered.

Children.

The usual recommended daily dosage for children is 25 to 50 mg/kg in divided doses. For streptococcal pharyngitis in patients over 1 year of age, tonsillitis, mild, uncomplicated urinary tract infection, and skin and soft tissue infections, the total daily dose may be divided and administered every twelve hours (see Table 1).
In severe infections, the dosage may be doubled. In the therapy of otitis media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in four divided doses is recommended.
In the treatment of β-haemolytic streptococcal infections, a therapeutic dosage of cefalexin should be administered for at least 10 days.

Impaired renal function.

See Section 4.4 Special Warnings and Precautions for Use.

4.3 Contraindications

Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics or who have previously experienced a major allergy to penicillin (see Section 4.4 Special Warnings and Precautions for Use).

4.4 Special Warnings and Precautions for Use

Before instituting therapy with cefalexin, every attempt should be made to determine if the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins, or other drugs. This product should be given cautiously to penicillin sensitive patients.
There is some clinical and laboratory evidence of partial cross allergenicity of the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both drugs.
If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the usual agents (e.g. adrenaline or other pressor amines, antihistamines or corticosteroids).
Pseudomembranous colitis has been reported with virtually all broad spectrum antibiotics (including macrolides, semisynthetic penicillins and cephalosporins). A toxin produced with Clostridium difficile appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against Cl. difficile should be considered. Fluids, electrolytes and protein replacement therapy should be provided when indicated. Drugs that delay peristalsis, e.g. opiates and diphenoxylate with atropine (e.g. Lomotil), may prolong and/or worsen the condition and should not be used.
Broad spectrum antibiotics should therefore be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Patients should be followed carefully so that any side effects or unusual manifestations of drug idiosyncrasy may be detected.
Prolonged use of cefalexin may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Seizure potential.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur, discontinue use of cefalexin. Anticonvulsant therapy can be given if clinically indicated.

Impaired renal function.

Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended.
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Paediatric use.

No data available.

Use in the elderly.

No data available.

Severe cutaneous adverse reactions.

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in patients taking beta-lactam antibiotics. When SCAR is suspected, cefalexin should be discontinued immediately and an alternative treatment should be considered.

Effects on laboratory tests.

The quantitative determination of urinary protein excretion using strong acids is misleading during cefalexin therapy as precipitation of cefalexin in the urine may occur.
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution or with Clinitest.
Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies or in transfusion cross matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborn infants whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

4.5 Interactions with Other Medicines and Other Forms of Interactions

As with other β-lactams, the renal excretion of cefalexin is inhibited by probenecid.
In healthy subjects given single 500 mg doses of cefalexin and metformin, plasma metformin Cmax and AUC increased by an average of 34% and 24%, respectively, and metformin renal clearance decreased by an average of 14%. The interaction of cefalexin and metformin following multiple dose administration has not been studied. Administration of a cephalosporin to a metformin-treated patient may result in increased metformin exposure.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category A)
Laboratory experiments with animals and clinical experience show no evidence of teratogenicity with cefalexin, but as with all drugs, cefalexin should be administered with caution during all stages of pregnancy.
Category A: drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.
Cefalexin is excreted in the milk. Caution should be exercised when cefalexin is administered to a breastfeeding woman. Alternative feeding arrangements for the infant should be considered.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Adverse drug reactions reported with cefalexin are very rare (< 0.01%) and are listed below.

Blood and lymphatic system disorders.

Eosinophilia, neutropenia, thrombocytopenia and haemolytic anaemia.

Gastrointestinal disorders.

Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain.

General disorders and administration site conditions.

Fatigue.

Hepatobiliary disorders.

Cholestatic jaundice, transient hepatitis, elevated SGOT, elevated SGPT.

Immune system disorders.

Allergic reactions, urticaria, angioedema.
These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported.

Infections and infestations.

Pseudomembranous colitis.

Musculoskeletal and connective tissue disorders.

Arthralgia, arthritis and joint disorders.

Nervous system disorders.

Dizziness, headache, seizure potential.

Psychiatric disorders.

Hallucinations, agitation, confusion.

Renal and urinary disorders.

Reversible interstitial nephritis.

Reproductive and breast disorders.

Genital and anal pruritus, genital moniliasis, vaginitis and vaginal discharge.

Skin and subcutaneous tissue disorders.

Rash, erythema multiforme.
These reactions usually subsided upon discontinuation of the drug.
Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in beta-lactam antibiotics.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems and contact Arrotex Medical Information Enquiries/Adverse Drug Reaction Reporting on 1800 195 055.

4.9 Overdose

Symptoms.

There is no definite experience of poisoning or severe overdosage with cefalexin. However, clinical features of overdosage may be similar to those seen with other cephalosporins and penicillins, i.e. convulsions, hallucinations, hyperreflexia, electrolyte imbalance, gastrointestinal disturbances and haematuria.

Treatment.

In the event of severe overdosage, general supportive care is recommended including close clinical and laboratory monitoring of haematological, renal, hepatic functions and coagulation status until the patient is stable.
Forced diuresis, peritoneal dialysis, haemodialysis or charcoal haemoperfusion have not been established as beneficial for an overdose of cefalexin.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

In vitro tests demonstrate that the cephalosporins are bactericidal because they inhibit cell wall synthesis. Cefalexin is active against the following organisms in vitro: β-haemolytic Streptococci; Staphylococci, including coagulase positive, coagulase negative, and penicillinase producing strains; Streptococcus (Diplococcus) pneumoniae; Escherichia coli; Proteus mirabilis; Klebsiella sp.

Note.

Most strains of Enterococci (Enterococcus faecalis) and a few strains of Staphylococci are resistant to cefalexin. It is not active against most strains of Enterobacter sp., Morganella morganii (formerly Pr. morganii), and Pr. vulgaris.
It has no activity against Pseudomonas or Acinetobacter calcoaceticus (formerly Mima and Herellea sp.). When tested by in vitro methods, Staphylococci exhibit cross resistance between cefalexin and methicillin type antibiotics.

Disc susceptibility tests.

Dilution or diffusion techniques, either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.
A report of "susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Note.

The prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.

Minimal inhibitory concentration (MIC) breakpoints.

Zone diameters, reported off cephalothin discs, are provided with corresponding breakpoints (see Table 2):

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption and distribution.

Cefalexin is acid stable and may be given without regard to meals. It is rapidly absorbed after oral administration. Following a dose of 250 mg, 500 mg and 1 g, average peak serum levels of approximately 9, 18, and 32 microgram/mL, respectively, were obtained at one hour. Measurable levels were present six hours after administration.

Metabolism and excretion.

Cefalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies have shown that over 90% of the drug is excreted unchanged in the urine within 8 hours. During this period, reported peak urine concentrations following 250 mg, 500 mg and 1 g doses were approximately 1,000, 2,200 and 5,000 microgram/mL, respectively.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Lactose monohydrate, gelatin, iron oxide yellow, brilliant blue FCF, sunset yellow FCF, titanium dioxide, magnesium stearate, TekPrint SW-9008 black ink, purified water.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from moisture. Protect from light.

6.5 Nature and Contents of Container

APO-Cephalexin 250 mg capsules.

Blister pack of 20 capsules: AUST R 73870.

APO-Cephalexin 500 mg capsules.

Blister pack of 20 capsules: AUST R 133852.
Not all strengths may be available.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

A semi-synthetic cephalosporin antibiotic for oral administration. The nucleus of cefalexin is related to that of other cephalosporin antibiotics. The compound is a zwitterion; i.e. the molecule contains both a basic and an acidic group. The isoelectric point of cefalexin in water is approximately 4.5 to 5.
The crystalline form of cefalexin, which is available, is a monohydrate. It is a white or almost white crystalline solid having a bitter taste. Solubility in water is about 1% at room temperature. It is practically insoluble in alcohol and in ether.
The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cefalexin has a d-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.

Chemical structure.


Chemical Name: (6R,7R)-7-[[(R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate.
Molecular Formula: C16H17N30O4S.H2O.
Molecular Weight: 365.41.

CAS number.

23325-78-2.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes